ERBB2 and breast carcinoma: Further research is being conducted to test the survival outcome of patients with advanced HER2+ breast cancer and CNS involvement—including patients with LM—with new HER2‐targeted treatments with or without RT (ClinicalTrials.gov identifiers NCT04420598, NCT04856475, NCT03661424, NCT04457596) and MRI screening (ClinicalTrials.gov identifier NCT04030507).